Abstract
FK506 binding proteins 12 and 12.6 (FKBP12 and FKBP12.6) are intracellular receptors for the immunosuppressant drug FK506 (ref. 1). The skeletal muscle ryanodine receptor (RyR1) is isolated as a hetero-oligomer with FKBP12 (ref. 2), whereas the cardiac ryanodine receptor (RyR2) more selectively associates with FKBP12.6 (refs 3, 4, 5). FKBP12 modulates Ca2+ release from the sarcoplasmic reticulum in skeletal muscle6,7 and developmental cardiac defects have been reported in FKBP12-deficient mice8, but the role of FKBP12.6 in cardiac excitation–contraction coupling remains unclear. Here we show that disruption of the FKBP12.6 gene in mice results in cardiac hypertrophy in male mice, but not in females. Female hearts are normal, despite the fact that male and female knockout mice display similar dysregulation of Ca2+ release, seen as increases in the amplitude and duration of Ca2+ sparks and calcium-induced calcium release gain. Female FKBP12.6-null mice treated with tamoxifen, an oestrogen receptor antagonist, develop cardiac hypertrophy similar to that of male mice. We conclude that FKBP12.6 modulates cardiac excitation–contraction coupling and that oestrogen plays a protective role in the hypertrophic response of the heart to Ca2+ dysregulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marks, A. R. Cellular functions of immunophilins. Physiol. Rev. 76, 631–649 (1996).
Jayaraman, T. et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J. Biol. Chem. 267, 9474–9477 (1992).
Lam, E. et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J. Biol. Chem. 270, 26511–26522 (1995).
Timerman, A. P. et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J. Biol. Chem. 271, 20385–20391 (1996).
Xin, H. B., Rogers, K., Qi, Y., Kanematsu, T. & Fleischer, S. Three amino acid residues determine selective binding of FK506-binding protein 12.6 to the cardiac ryanodine receptor. J. Biol. Chem. 274, 15315–15319 (1999).
Timerman, A. P. et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 268, 22992–22999 (1993).
Brillantes, A. B. et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 77, 513–523 (1994).
Shou, W. et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391, 489–492 (1998).
Fleischer, S. & Inui, M. Biochemistry and biophysics of excitation–contraction coupling. Annu. Rev. Biophys. Biophys. Chem. 18, 333–364 (1989).
Meissner, G. Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors. Annu. Rev. Physiol. 56, 485–508 (1994).
Timerman, A. P., Wiederrecht, G., Marcy, A. & Fleischer, S. Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. J. Biol. Chem. 270, 2451–2459 (1995).
Barg, S., Copello, J. A. & Fleischer, S. Different interactions of cardiac and skeletal muscle ryanodine receptors with FK-506 binding protein isoforms. Am. J. Physiol. 272, C1726–C1733 (1997).
Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L. & Clardy, J. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 252, 839–842 (1991).
Aldape, R. A. et al. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. J. Biol. Chem. 267, 16029–16032 (1992).
Wang, Y.-X. & Kotlikoff, M. I. Inactivation of calcium-activated chloride channels in smooth muscle by calcium/calmodulin dependent protein kinase. Proc. Natl Acad. Sci. USA 94, 14918–14923 (1997).
Collier, M. L., Ji, G., Wang, Y. & Kotlikoff, M. I. Calcium-induced calcium release in smooth muscle: loose coupling between the action potential and calcium release. J. Gen. Physiol. 115, 653–662 (2000).
Shorofsky, S. R. et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ. Res. 84, 424–434 (1999).
Fentzke, R. C. et al. Evaluation of ventricular and arterial hemodynamics in anesthetized closed-chest mice. J. Am. Soc. Echocardiogr. 10, 915–925 (1997).
Louie, E. K. & Edwards, L. C. III Hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 36, 275–308 (1994).
Levy, D. et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann. Intern. Med. 108, 7–13 (1988).
Lim, W. K., Wren, B., Jepson, N., Roy, S. & Caplan, G. Effect of hormone replacement therapy on left ventricular hypertrophy. Am. J. Cardiol. 83, 1132–1134 (1999).
Gomez, A. M. et al. Defective excitation–contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276, 800–806 (1997).
Marx, S. O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365–376 (2000).
Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
Falvo, J. V. et al. Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol. Cell Biol. 20, 2239–2247 (2000).
Kadokami, T., McTiernan, C. F., Kubota, T., Frye, C. S. & Feldman, A. M. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J. Clin. Invest. 106, 589–597 (2000).
Pelzer, T., Shamim, A., Wolfges, S., Schumann, M. & Neyses, L. Modulation of cardiac hypertrophy by estrogens. Adv. Exp. Med. Biol. 432, 83–89 (1997).
Hulley, S. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280, 605–613 (1998).
Hayward, C. S., Kelly, R. P. & Collins, P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc. Res. 46, 28–49 (2000).
Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153–1163 (1991).
Acknowledgements
Histology was carried out at the Vascular Histology and Imaging Core Vanderbilt Division of Cardiology. We thank J. V. Barnett and L. Gleaves for advice and help in preparing the histological sections, J. B. Atkinson for analysing the histological sections, and E. Price for blood-pressure measurements. The production of the FKBP12.6 knockout mouse was achieved with the aid of the Vanderbilt Transgenic/ES Cell Shared Resource Lab. We thank M. Sutherland for help in this regard. This work was supported by grants from the NIH to S.F., T.I., M.M., Y.-X.W. and M.I.K., and a Discovery Grant from Vanderbilt University (S.F.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no competing financial interests
Supplementary information
Rights and permissions
About this article
Cite this article
Xin, HB., Senbonmatsu, T., Cheng, DS. et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416, 334–337 (2002). https://doi.org/10.1038/416334a
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/416334a
This article is cited by
-
Role of lateral amygdala calstabin2 in regulation of fear memory
Molecular Brain (2020)
-
Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-ÎşB/cyclin D1 pathway
Nature Communications (2020)
-
Oestrogen Receptor β Activation Protects Against Myocardial Infarction via Notch1 Signalling
Cardiovascular Drugs and Therapy (2020)
-
Degrading proteins in animals: “PROTAC”tion goes in vivo
Cell Research (2019)
-
Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster
BMC Developmental Biology (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.